NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • Welcome Guide
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Case Studies
    • Patient and Public Involvement and Engagement (PPIE) Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
    • Public events
    • Patient & Public Involvement events
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cancer > Classification system uncovers new information about ovarian cancers

Classification system uncovers new information about ovarian cancers

18 January 2021 · Listed under Cancer

An Oxford-based ovarian cancer specialist has published a paper outlining a new classification which categorises different subtypes of cells and determines which ones can lead to more severe cancer outcomes.

Prof-Ahmed Ahmed-(Image: Ovarian Cancer Action)

This approach, dubbed the ‘Oxford Classification of Carcinoma of the Ovary’ or ‘Oxford Classic’ for short, was developed by Professor Ahmed Ahmed, who is supported by the NIHR Oxford Biomedical Research Centre.

In 2020, using single cell RNA sequencing, Prof Ahmed’s team made a breakthrough by identifying new types of fallopian tube cells that are the cells of origin for the majority of ovarian cancers.

They showed that that the types of these newly-discovered non-cancer cells are ‘mirrored’ into different ovarian cancer subtypes. These subtypes correlated well with survival.

Discovering the new subtypes of cells has allowed the Oxford researchers to classify and categorise tumours based on their origin in the body, and determine which ones can lead to more severe cancer outcomes.

This Oxford Classic approach will provide much more accurate predictions for disease outcome in patients, as well as helping researchers to develop targeted therapies for each type of cancer

Prof Ahmed, of the Nuffield Department of Women’s and Reproductive Health and Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine, has how published a paper in collaboration with Imperial College demonstrating the applications of the Oxford Classic approach, as well as shedding light on some previously unknown information about ovarian cancers.

Prof Ahmed said: “Our group is very excited that we were able to confirm the predictive role of the Oxford Classic. This work highlights that it is now important to identify new personalised therapies for the Oxford Classic-defined EMT-high ovarian cancer subtype.

“The finding that there is a strong connection with abundant M2 Macrophages already offers a good hint as to where we could find good treatment options for patients with this type.”

Read more via the Cancer Research UK Oxford Centre.

Read the fully study.

← Using AI to improve the quality of endoscopy videos
New clinical prediction tools for myeloma developed →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre